Bone Abstracts

Background: Recently, the prevalence of osteoporosis and sarcopenia in the elderly has dramatically increased. However the relationship between theses disease is not clear.Object: We aimed to determine the independent relations of muscle mass to osteoporosis (femur neck) in relation to body weight, fat mass, and other confounders.Design: We analyzed body composition and BMD data of 570 males and 734 females who are older than 65 ye...

Purpose: Denosumab is a new potent antiresorptive treatment of osteoporosis that can potentially induce a compensatory increase of parathyroid hormone (PTH) levels. We aimed to evaluate the alteration of PTH 1 and 6 months after denosumab’s administration (60 mg) with different regimens of calcium and vitamin D (Ca/D) supplementation, as well as the association of PTH with serum Ca and bone markers.Methods: This was a prospective, multicenter, study...

Many reports have proposed significant role of vitamin D on immune mediated disease. This study analyzed lymphocyte subsets according to serum 25(OH) vitamin D levels in postmenopausal women to determine the potential effect of vitamin D on immune-mediated disease.On a prospective observational basis, we enrolled 31 postmenopausal women who underwent health checkup in our hospital. Peripheral blood drawn for the estimation of total T, B cell, NK cell cou...

Eldecalcitol (ED-71; ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, was approved to treat osteoporosis in Japan in 2011. The endothelial protective effect of vitamin D3 in osteoporosis is not clear. This study evaluated the endothelial protective effect of ELD in ovariectomized (OVX) rats.ELD (20 ng/kg) was orally administered five times a week for 4 weeks from 1 day after OVX surgery. Four weeks after surgery, flow-mediated dilation (...

Context: As bone metabolic markers, recent studies indicated vitamin D and osteocalcin (OC) were also involved in energy metabolism. While the exact relationship between vitamin D and OC in regulating energy metabolism is unclear. One of the possibilities is that: low vitamin D could lead to secondary hyperparathyroidism and following high bone turnover, which would enhance the quantity of bioactive OC.Objective: Our aim was to study whether OC mediated ...

Optineurin (OPTN) is a protein encoded by the OPTN gene. This protein is involved in several cellular mechanisms such as autophagy, NF-κB signaling, cellular morphogenesis, membrane and vesicle trafficking, and transcription activation. Mutations in OPTN have been described in glaucoma, amyotrophic lateral sclerosis and other neurological diseases. More recently, a polymorphism in this gene was also identified by a genome wide association study to be ass...

Bone fractures may depend on Vitamin D Receptor Gene (VDR), bone mineral density, bone turnover markers.Patients and methods: About 161 patients were recruited and underwent: skeletal densitometry (DXA) method and bone turnover studies (Osteocalcin and Ntx).The study group was evaluated using restriction enzyme digestion at BsmI (rs1544410), FokI (rs2228570), ApaI (rs7975232) and TaqI (rs731236), polymorphic sites of t...

Vitamin D deficiency is common in older persons and non-western immigrants. Vitamin D is often started in loading doses of 50 000 IU/ml solution. Though, generally considered safe, this highly concentrated solution carries some risks as is illustrated by the following cases. A woman of >80 years old was admitted with hypercalcemia, calcium 3.27 mmol/l. She complained of nausea, thirst and polyuria for 3 months. History included cholecystitis, atrial fibrillation, myocardia...

The therapy of osteoporosis in patients with end organ failure and after the transplantation (Tx) becomes more frequent problem with the better patients and graft survival rates. Moreover some of these patients have impaired renal function and therefore cannot use bisphosphonates. The supplementation therapy with calcium and/or vitamin D is frequently not sufficient to improve bone mass. The possible innovative therapy is Denosumab (Prolia inj.) - MAB to RANK, which is not con...

Background: Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by hyperphosphatemia and the formation of tumor-like extra-osseous calcifications. Tumors often necessitate surgical management although medical treatment may limit the need for surgical intervention. We present two cases of HFTC successfully managed with combination acetazolamide (ACTZ) and sevelamer carbonate.Case Report #1: A 5-year-old African boy with a loss-of-functio...